Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026
Seer announced that Nanyang Technological University researchers will present early PRECISE-SG100K findings at the HUPO 2026 World Congress in Singapore, September 27 to October 1.
The study applied Seer's Proteograph Product Suite with mass spectrometry to deeply profile the plasma proteome of 10,000 participants within a Singapore cohort of over 100,000, with Seer citing a 7 to 10-fold increase in protein coverage depth versus direct plasma analysis.
Early proteogenomic and epidemiological signals reportedly show potential to accelerate biomarker discovery, reinforcing Seer's positioning in population-scale proteomics, though no commercial or financial results were disclosed.